Probiotic prophylaxis in predicted severe acute pancreatitis.

摘要

The International Scientific Association for Probiotics and Prebiotics wishes to register serious concerns with the paper by Marc Besselink and colleagues (Feb 23, p 651).1 The term probiotic requires that a product has been adequately tested for safety and proven to confer a health benefit.2 Ecologic 641 does not meet this requirement on the basis of published data. The inhibition of pathogens in vitro and reduced onset of pancreatitis in animals is not suitable justification for the use of this substance as a primary treatment for acute pancreatitis.3 The failure to reduce C-reactive protein also illustrates that in-vitro immune modulation did not translate into a clinical anti-inflammatory effect.